ARGX ARGENX SE

Nasdaq argenx.com


$ 835.63 $ -4.35 (-0.52 %)    

Wednesday, 29-Oct-2025 10:39:49 EDT
QQQ $ 636.37 $ 0.82 (0.13 %)
DIA $ 479.35 $ 0.76 (0.16 %)
SPY $ 688.71 $ -0.05 (-0.01 %)
TLT $ 91.72 $ -0.16 (-0.17 %)
GLD $ 369.24 $ -0.41 (-0.11 %)
$ 836.39
$ 841.33
$ 835.31 x 20
$ 836.21 x 10
$ 831.90 - $ 841.33
$ 510.06 - $ 855.46
266,095
na
50.82B
$ 0.63
$ 61.01
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 argenx-to-present-vyvgart-and-empasiprubart-data-at-aanem-annual-meeting-and-mgfa-scientific-session-in-san-francisco

Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART's potential to treat broad set of myasthenia gravis ...

 wedbush-maintains-outperform-on-argenx-raises-price-target-to-880

Wedbush analyst David Nierengarten maintains argenx (NASDAQ:ARGX) with a Outperform and raises the price target from $800 to...

 morgan-stanley-maintains-overweight-on-argenx-raises-price-target-to-1040

Morgan Stanley analyst Matthew Harrison maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $7...

 heres-how-much-100-invested-in-argenx-5-years-ago-would-be-worth-today

argenx (NASDAQ: ARGX) has outperformed the market over the past 5 years by 7.61% on an annualized basis producing an average an...

 price-over-earnings-overview-argenx

In the current market session, argenx Inc. (NASDAQ: ARGX) share price is at $711.62, after a 0.07% increase. Moreover, over the...

 guggenheim-reiterates-buy-on-argenx-maintains-1070-price-target

Guggenheim analyst Yatin Suneja reiterates argenx (NASDAQ:ARGX) with a Buy and maintains $1070 price target.

 fujifilm-biotechnologies-expands-strategic-partnership-with-argenx-to-include-us-manufacturing-operations

Expansion of partnership broadens argenx' manufacturing capabilities in the U.S., supporting its strategy of local-for-loca...

 truist-securities-maintains-buy-on-argenx-raises-price-target-to-918

Truist Securities analyst Joon Lee maintains argenx (NASDAQ:ARGX) with a Buy and raises the price target from $700 to $918.

 b-of-a-securities-maintains-buy-on-argenx-raises-price-target-to-887

B of A Securities analyst Tazeen Ahmad maintains argenx (NASDAQ:ARGX) with a Buy and raises the price target from $880 to $887.

 argenx-immune-disorder-drugs-reach-could-get-much-bigger-with-major-trial-win

Argenx advances Vyvgart with strong trial data in seronegative gMG, driving growth projections and reinforcing its leadership i...

 regeneron-advances-in-rare-disease-race-with-positive-autoimmune-muscle-disorder-trial-data

Regeneron's Phase 3 NIMBLE trial showed cemdisiran improved myasthenia gravis symptoms, with an FDA filing expected in earl...

 piper-sandler-maintains-overweight-on-argenx-raises-price-target-to-820

Piper Sandler analyst Allison Bratzel maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $750...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION